AGS-004: Phase IIb started

Argos began a double-blind, placebo-controlled, U.S. and Canadian Phase IIb trial to evaluate injectable AGS-004 in 42 patients. Under a 2004 deal, Kirin has an option to co-develop AGS-004 after Phas...